Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of osteosarcoma, the company announced recently.

“Cellectar is pleased to have the opportunity to work closely with the FDA on our planned Phase 1 trial for these indications and we remain committed to advancing the pediatric programs as rapidly as possible,” Cellectar Biosciences Chief Medical Officer John Friend said in a statement.

According to a release, since May 2018, the company also has received RPDD for CLR 131 for neuroblastoma, rhabdomyosarcoma and Ewing’s Sarcoma.

Osteosarcoma is the most commonly diagnosed primary bone malignancy among children and adolescents.